Advertisement

Advertisement
Skin Cancer
Immunotherapy
Issues in Oncology

Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma

Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma...

Gynecologic Cancers

Cisplatin, Gemcitabine, and IMRT in Locally Advanced Vulvar Cancer

In a phase II trial (NRG Oncology/GOG Study 279) reported in the Journal of Clinical Oncology, Horowitz et al found that concurrent cisplatin, gemcitabine...

Breast Cancer

HER2-Positive Early Breast Cancer: PET-Based, pCR-Adapted Strategy

In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response...


Advertisement
Breast Cancer
Global Cancer Care

A Pioneering Female Oncologist in Morocco Helps Advance the Global Shift Toward Gender Equity in Academia

Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation...

Breast Cancer

Giredestrant in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer

In the phase II acelERA BC trial reported in the Journal of Clinical OncologyMiguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER)...

Advertisement
Advertisement




Sponsored Content


Gynecologic Cancers

Linda R. Mileshkin, MBBS, MD, on Cervical Cancer: Adjuvant Chemotherapy After Chemoradiation

Bladder Cancer
Immunotherapy

Pembrolizumab in BCG-Unresponsive High-Risk Non–Muscle Invasive Bladder Cancer: KEYNOTE-057

As reported in The Lancet Oncology by Arjun V. Balar, MD, and colleagues, the phase II KEYNOTE-057 trial showed that pembrolizumab produced enduring responses in a cohort of patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG) who were ineligible ...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Issues in Oncology
Health-Care Policy
Legislation

Jingxuan Zhao, MPH, on How Medicaid Expansion Affects Long-Term Cancer Survival

Breast Cancer
Immunotherapy

Noninvasive Imaging Biomarker and Pathologic Complete Response to Neoadjuvant Pertuzumab/Trastuzumab in HER2-Positive Breast Cancer

As reported in the Journal of Clinical Oncology by Roisin M. Connolly, MD, and colleagues, updated results of the phase II TBCRC026 trial indicate an association of early F-18 fluorodeoxyglucose positron-emission tomography/computed tomography (F-18 FDG PET/CT) maximum standardized uptake value...

Bladder Cancer
Immunotherapy

Choice of First-Line Platinum Chemotherapy Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Urothelial Carcinoma

In a presentation of real-world data given during the 2021 ASCO Annual Meeting, Miron et al concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Lung Cancer
Immunotherapy

Heather A. Wakelee, MD, on NSCLC: Atezolizumab vs Best Supportive Care After Chemotherapy

Gynecologic Cancers

OUTBACK Trial: No Survival Benefit With Adjuvant Chemotherapy After Standard Chemoradiation for Locally Advanced Cervical Cancer

Cervical cancer is the fourth most common cancer in women worldwide, and the leading cause of cancer-related death among women in Eastern, Western, Middle, and Southern Africa. Globally, in 2018, approximately 570,000 women were diagnosed with cervical cancer, and 311,000 women died. In the United...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter